Selenophosphate synthetase 1 (SEPHS1) plays an essential role in the metabolism of selenium and has ATPase activity that synthesizes selenophosphate from ATP and selenide. Researchers have hypothesized the potential involvement of SEPHS1 in genetic disorders. They presented a series of case reports involving 9 individuals with heterozygous missense variants in the SEPHS1 gene; all these variants resided in the C-terminal domain or near the AIR synthase-related domain of the gene.
Neuromyelitis optica-related disorder (NMORD) consists of a spectrum of diseases characterized by recurrent optic neuritis and/or myelitis, with most cases being associated with a pathogenic antibody against aquaporin-4 (AQP4-Abs) or antibodies targeting the myelin oligodendrocyte glycoprotein (MOG-Abs).
Sunovion Pharmaceuticals Inc. has identified chroman and benzofuran derivatives acting as 5-HT1A and trace amine-associated receptor 1 (TAAR1) agonists reported to be useful for the treatment of depression.
The failure to remyelinate neurons following an attack is one of the major characteristics of multiple sclerosis (MS) ultimately causing the progressive loss of neurological dysfunction.
Satellos Bioscience Inc. has created, prioritized and advanced novel small-molecule drug candidates into further preclinical studies. The company's compounds have been designed to be potent and selective inhibitors of a particular kinase protein in the Notch pathway.